title: Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.
abstract: The diagnosis of malignant pleural effusions may be challenging when cytological examination of aspirated pleural fluid is equivocal or noncontributory. The purpose of this study was to identify protein candidate biomarkers differentially expressed in the pleural fluid of patients with mesothelioma, lung adenocarcinoma, lymphoma, and tuberculosis (TB).A multiplex protein biochip comprising 120 biomarkers was used to determine the pleural fluid protein profile of 29 mesotheliomas, 29 lung adenocarcinomas, 12 lymphomas, and 35 tuberculosis. The relative abundance of these predetermined biomarkers among groups served to establish the differential diagnosis of: malignant versus benign (TB) effusions, lung adenocarcinoma versus mesothelioma, and lymphoma versus TB. The selected putative markers were validated using widely available commercial techniques in an independent sample of 102 patients.Significant differences were found in the protein expressions of metalloproteinase-9 (MMP-9), cathepsin-B, C-reactive protein, and chondroitin sulfate between malignant and TB effusions. When integrated into a scoring model, these proteins yielded 85% sensitivity, 100% specificity, and an area under the curve (AUC) of 0.98 for labeling malignancy in the verification sample. For lung adenocarcinoma-mesothelioma discrimination, combining CA19-9, CA15-3, and kallikrein-12 had maximal discriminatory capacity (65% sensitivity, 100% specificity, AUC 0.94); figures which also refer to the validation set. Last, cathepsin-B in isolation was only moderately useful (sensitivity 89%, specificity 62%, AUC 0.75) in separating lymphomatous and TB effusions. However, this last differentiation improved significantly when cathepsin-B was used with respect to the patient's age (sensitivity 72%, specificity 100%, AUC 0.94).In conclusion, panels of 4 (i.e., MMP-9, cathepsin-B, C-reactive protein, chondroitin sulfate), or 3 (i.e., CA19-9, CA15-3, kallikrein-12) different protein biomarkers on pleural fluid samples are highly discriminative for signaling a malignant versus tuberculous effusion, or lung adenocarcinoma versus mesothelioma, respectively. Cathepsin-B could also be helpful in establishing the presence of a lymphomatous effusion versus that of TB, if the patient's age is simultaneously taken into consideration.
authors.affiliation: From the Pleural Medicine Unit (JMP, SB); Departments of Internal Medicine, Laboratory Medicine (AE); Biostatistics (MMA); and Oncology-Hematology (AS), Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Porcel
authors.forename: Aureli
authors.initials: A
authors.lastname: Esquerda
authors.forename: Montserrat
authors.initials: M
authors.lastname: Martínez-Alonso
authors.forename: Silvia
authors.initials: S
authors.lastname: Bielsa
authors.forename: Antonieta
authors.initials: A
authors.lastname: Salud
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D000069258:Thoracentesis; D013899:Thoracic Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor